Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prostate-specific antigen RNA-pulsed dendritic cell vaccine
- Development stage
- Phase 2
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intradermal, Subcutaneous
01
Overview
The prostate-specific antigen (PSA) RNA-pulsed dendritic cell (DC) vaccine is an autologous cellular immunotherapy designed to treat prostate cancer. The therapy involves isolating a patient's own dendritic cells and loading them with messenger RNA encoding the tumor-associated antigen PSA, typically via electroporation or co-incubation. These modified DCs are then reintroduced into the patient to stimulate a robust T-cell–mediated immune response specifically targeting PSA-expressing prostate cancer cells. This approach aims to overcome immune tolerance and induce cytotoxic T lymphocyte activity against tumor cells. Clinical studies have demonstrated that this strategy can reliably induce PSA-specific T-cell responses in patients with metastatic or recurrent prostate cancer, with evidence of decreased serum PSA levels and transient clearance of circulating tumor cells in some cases[1][4]. The method is considered safe and feasible for clinical use[4].
- Other names
- PSA RNA-loaded dendritic cell vaccinePSA mRNA-transfected DC vaccinePSA RNA-DC vaccine
02
Targets
PSA-specific T-cell receptor
Beyond the preview
Go deeper on prostate-specific antigen RNA-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prostate-specific antigen RNA-pulsed dendritic cell vaccine.